We are monitoring the impact of COVID-19 on Latin America Diabetic Retinopathy Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 879
Share on
Share on

Latin America Diabetic Retinopathy Market Research Report - Segmented By Treatment Type, Indication, End User, By Country (Mexico, Brazil, Argentina, Chile and Rest of Latin America) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 879
Pages: 140

Latin American Diabetic Retinopathy Market Size (2021 to 2026)

The size of the Latin America Diabetic Retinopathy Market is forecasted to value USD 1.40 billion by 2026 from USD 0.97 billion in 2021, growing at a CAGR of 7.69% during the forecast period.

Latin America is projected to account for a considerable share in the global market during the forecast period. Favorable government initiatives and clinical guidelines are expected to increase the diagnosis and treatment rate, thereby fuelling the market's growth in the region.

Diabetes is a long-lasting condition associated with an abnormally high level of glucose in the blood. Deficient or non-production of insulin in the pancreas causes diabetes. Diabetic retinopathy is the most common complication of diabetes that affects the eyes. People suffering from diabetes type I and II have the threat of developing diabetic retinopathy. Swelling or leakage of blood vessels of the retina is the cause of the disease.

Increasing occurrences of diabetes, a growing geriatric population base, and the rising demand for early detection are key drivers of the Latin American diabetic retinopathy market. Furthermore, refining healthcare infrastructure, increasing demand for cost-effective and safe treatment, and rising focus of market players in developing regions are also predicted to propel market growth.

An increase in the older population, along with a growing demand for cataract surgery and age-related changes to the eye, has resulted in a shortage of qualified ophthalmologists. In addition, people are hesitant to undergo therapy because of the rising costs of treatments and drugs, further limiting the market growth. Also, there is an increase in the market players having alternative treatments with convenient pricing due to extended approval time for drugs. However, it is very time-consuming and has lengthy procedures that can affect market growth adversely.

This research report on the Latin American diabetic retinopathy market has been segmented and sub-segmented into the following categories:

By Treatment Type:

  • Anti-Vascular Endothelial Growth Factor (VEGF) drug
  • Intraocular Steroid Injection
  • Laser Surgery
  • Vitrectomy     

By Indication:

  • Non-Proliferative Diabetic Retinopathy (NPDR)
    • Mild
    • Moderate
    • Severe
  • Proliferative Diabetic Retinopathy (PDR) 

By End-User:

  • Hospitals
  • Ophthalmic Clinics
  • Ambulatory Surgical Centers

By Country:

  • Mexico
  • Brazil
  • Argentina
  • Chile
  • Rest of Latin America

Geographically, the Latin American diabetic retinopathy market is expected to witness a moderate share in the global diabetic retinopathy market during the forecast period. Retinopathy is a silent illness that leads to blindness, affects one out of every three diabetes patients, although physicians little recognize it at public health facilities. According to the Mexican Council of Ophthalmology, it takes 5-15 years for a person with diabetes to acquire this problem, depending on their level of care and clinical management. 

In Latin America, the incidence of type 1 diabetes ranges from 0.4 to 8.3 instances per 100000 children under the age of 15. In contrast, the prevalence of type 2 diabetes ranges from 1.2 to 8%, with greater rates in metropolitan regions.

However, the diagnosis by the general practitioner is delayed in half of the instances. Diabetic retinopathy is the world's third most common cause of permanent blindness. The general public is becoming more aware of the different treatment options and the advantages of early identification of diabetic retinopathy.

As a result, technologically enhanced techniques and equipment, such as better ocular diagnostic and surgical instruments, have become widely adopted. These techniques and technology allow for early identification and effective treatment of the disease with greater precision and less patient discomfort.

KEY MARKET PLAYERS:

Companies playing a notable role in the Latin American Diabetic Retinopathy Market profiled in the report are Bayer AG, Pfizer Inc., Hoffmann-La Roche Ltd., Regeneron Pharmaceutical Inc., Novartis AG, Valeant Pharmaceutical International Inc., Abbott Laboratories Inc., Alimera Science Inc., and Ampio Pharmaceuticals Inc.

1. Introduction                                                 

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                           

                1.4 General Study Assumptions                                

2. Research Methodology                                                           

                2.1 Introduction                                              

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                            

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                     

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

3. Overview                                                      

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 New Developments                                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                      

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                               

5. Market Segmentation                                                              

                5.1 By Type of Treatment                                            

                                5.1.1 Anti-Vascular Endothelial Growth Factor (VEGF) drug                          

                                5.1.2 Intraocular Steroid Injection                           

                                5.1.3 Laser Surgery                         

                                5.1.4 Vitrectomy                             

                5.2 By Indication                                              

                                5.2.1 Non-Proliferative Diabetic Retinopathy (NPDR)                      

                                                5.2.1.1 Mild       

                                                5.2.1.2 Moderate            

                                                5.2.1.3 Severe  

                                5.2.2 Proliferative Diabetic Retinopathy (PDR)                    

                5.3 By End Users                                             

                                5.3.1 Hospitals                  

                                5.3.2 Ophthalmic Clinics                               

                                5.3.3 Ambulatory Surgical Centers                           

6. Geographical Analysis                                                              

                                6.1 Introduction                              

                                6.2 Brazil                             

                                6.3 Mexico                         

                                6.4 Argentina                    

                                6.5 Rest of Latin America                             

7. Strategic Analysis                                                       

                7.1 PESTLE analysis                                         

                                7.1.1 Political                     

                                7.1.2 Economic                 

                                7.1.3 Social                         

                                7.1.4 Technological                         

                                7.1.5 Legal                          

                                7.1.6 Environmental                      

                7.2 Porter’s Five analysis                                              

                                7.2.1 Bargaining Power of Suppliers                        

                                7.2.2 Bargaining Power of Consumers                    

                                7.2.3 Threat of New Entrants                     

                                7.2.4 Threat of Substitute Products and Services               

                                7.2.5 Competitive Rivalry within the Industry                      

8. Market Leaders' Analysis                                                        

                8.1 Bayer AG                                     

                                8.1.1 Overview                

                                8.1.2 Product Analysis                   

                                8.1.3 Strategic Evaluation and Operations                            

                                8.1.4 Financial analysis                  

                                8.1.5 Legal issues                            

                                8.1.6 Recent Developments                       

                                8.1.7 SWOT analysis                       

                                8.1.8 Analyst View                          

                8.2 Pfizer Inc.                                    

                8.3 Hoffmann-La Roche ltd                                          

                8.4 Regeneron Pharmaceutical Inc.                                         

                8.5 Novartis AG                                

                8.6 Valeant Pharmaceutical International Inc.                                     

                8.7 Abbott Laboratories Inc.                                       

                8.8 Alimera Science Inc.                                                

                8.9 Ampio Pharmaceuticals Inc.                                

9. Competitive Landscape                                                           

                9.1 Market share analysis                                            

                9.2 Merger and Acquisition Analysis                                        

                9.3 Agreements, collaborations and Joint Ventures                                          

                9.4 New Product Launches                                          

10. Expert Opinions                                                        

                10.1 Market Outlook                                     

                10.2 Investment Opportunities                                 

Appendix                                                           

                a) List of Tables                                

                b) List of Figures                                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Latin America Diabetic Retinopathy Market, By Region, From 2021 to 2026 (USD Million)
  2. Latin America Diabetic Retinopathy Market, By Treatment Type, From 2021 to 2026 (USD Million)
  3. Latin America Anti-Vascular Endothelial Growth Factor (VEGF) drug Market, By Region, From 2021 to 2026 (USD Million)
  4. Latin America Intraocular Steroid Injection Market, By Region, From 2021 to 2026 (USD Million)
  5. Latin America Laser Surgery Market, By Region, From 2021 to 2026 (USD Million)
  6. Latin America Vitrectomy Market, By Region, From 2021 to 2026 (USD Million)
  7. Latin America Diabetic Retinopathy Market, By Indication, From 2021 to 2026 (USD Million)
  8. Latin America Non-Proliferative Diabetic Retinopathy (NPDR) Market, By Region, From 2021 to 2026 (USD Million)
  9. Latin America Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2021 to 2026 (USD Million)
  10. Latin America Mild Indication Market, By Region, From 2021 to 2026 (USD Million)
  11. Latin America Moderate Indication Market, By Region, From 2021 to 2026 (USD Million)
  12. Latin America Severe Indication Market, By Region, From 2021 to 2026 (USD Million)
  13. Latin America Proliferative Diabetic Retinopathy (PDR) Market, By Region, From 2021 to 2026 (USD Million)
  14. Latin America Diabetic Retinopathy Market, By End Users, From 2021 to 2026 (USD Million)
  15. Latin America Hospitals Market, By Region, From 2021 to 2026 (USD Million)
  16. Latin America Ophthalmic Clinics Market, By Region, From 2021 to 2026 (USD Million)
  17. Latin America Ambulatory Surgical Centers Market, By Region, From 2021 to 2026 (USD Million)
  18. Brazil Diabetic Retinopathy Market, By Treatment Type, From 2021 to 2026 (USD Million)
  19. Brazil Diabetic Retinopathy Market, By Indication, From 2021 to 2026 (USD Million)
  20. Brazil Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2021 to 2026 (USD Million)
  21. Brazil Diabetic Retinopathy Market, By End Users, From 2021 to 2026 (USD Million)
  22. Argentina Diabetic Retinopathy Market, By Treatment Type, From 2021 to 2026 (USD Million)
  23. Argentina Diabetic Retinopathy Market, By Indication, From 2021 to 2026 (USD Million)
  24. Argentina Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2021 to 2026 (USD Million)
  25. Argentina Diabetic Retinopathy Market, By End Users, From 2021 to 2026 (USD Million)
  26. Mexico Diabetic Retinopathy Market, By Treatment Type, From 2021 to 2026 (USD Million)
  27. Mexico Diabetic Retinopathy Market, By Indication, From 2021 to 2026 (USD Million)
  28. Mexico Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2021 to 2026 (USD Million)
  29. Mexico Diabetic Retinopathy Market, By End Users, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample